Most Recent
Construction company Delcon Civil is facing a lawsuit by a subcontractor seeking over $3.4 million in damages for alleged breach of contract relating to work on the North East Link project.
Unilodge Australia faces a potential class action alleging the student housing agency shortchanged staff by paying them under the wrong award.
Burger giant Hungry Jack's has lost its bid to have McDonald's hand over test results showing the “pre-cooked” weight of its Big Mac beef patties, with a judge finding they were not relevant to whether the rival’s Big Jack burger had 25 per cent “more Aussie beef”.
A class action against Irish insurer Zurich Insurance Plc by unit owners of the defective New Zealand-based Victopia Apartments can proceed in Australia after the NSW Supreme Court ruled the case could not be filed elsewhere.
Nine Network has been hit with a class action by Indigenous Australians who say the broadcaster's coverage of a $30 million class action settlement being "rorted" by Palm Islanders was discriminatory and inaccurate.
The federal government will pay $2 million to settle a human rights class action brought by Indigenous Australians from the Ngaanyatjarraku community in Western Australia over allegedly discriminatory requirements for access to social security benefits.
Accounting giant Deloitte has lost its bid to throw out a former client's lawsuit alleging negligence and fraud over a failed interposition under tax law that occurred more than 16 years ago.
A Western Australian lawyer will face penalties and disciplinary action in the State Administrative Tribunal after nine professional misconduct findings were made against him, including a finding that he knowingly sought to mislead the Supreme Court.
A “full-blooded carriage fight” is set down for next year between two competing class actions alleging dairy giant a2 Milk misled shareholders with an overly optimistic prediction of its infant formula sales.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.